outperform price
hca core trend remain favor minim
temporari benefit flu quarter
mix acceler admiss faster medic growth
surgic account lower price growth
momentum continu strong core
growth supplement continu margin ramp recent
acquisit deal pipelin
balanc sheet low end long-term target
rang like hca signific capit deploy
option mix higher share repo
strong volum growth reliant flu
back network sierra la vega
confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
increas driven strong ss volum growth acquisit
growth across market servic fundament remain strong
spent bn capital-expenditure half routin need half growth
in-pati market share grew improv yoy
ss er visit increas higher acuiti visit increas admiss er
ebitda margin bp labor cost suppli cost grew
ss rev/equiv admiss acuiti growth lower trend surgic
admiss growth
bn avail revolv
op bn capital-expenditure bn bn interest expens
look cash op current level good plan
estim see opportun expand growth includ facil
expans growth cash flow strong invest op continu
savannah mission acquisit happen earli model lift
capital-expenditure revenu that dial back bit later stage
occup level continu go encourag prove roi
guidanc payer settlement could add growth rate
see momentum marketplac acquisit also increas growth
acquisit
see signific volum opportun drive growth
magnitud compani whole materi
materi la vega chang thing significantli
price commerci side
forecast materi dsh cut moment
good posit contract strategi
gain access sierra la vega expand commerci life access
commerci revenu underneath composit
contract
thought
due lower medic book outpati growth certain area
growth high-end servic neonat cardiovascular
medic growth creat net effect number report
portfolio market posit macro factor
see demandcommerci demand grew
pick share result network invest physician
leverag ratio lowest sinc lbo
continu evalu strateg acquisit expect small one
also evalu larger acquisit time balanc
expand capac expand capit spend
brought addit inpati bed
repo author top bn remain author
season ebitda margin
extrem strong quarter also includ payer settlement
pleas acquisit continu progress
expect margin continu evolv
histor trend best guid
look ytd basi rather quarter quarter
grow demand hca market pick market support macro
competit model that respons marketplac
conveni locat network patient
one-stop shop comprehens servic line
acquir urgent care center asc physician clinic
site care connect hospit oper system
signific leadership physician side
clinic specialti nurs care
grown physician year
physician engag all-tim high
invest heavili clinic improv
critic care intens care largest intens care
group countri
leverag learn data support better critic care
part strategyimport patient satisfact effici
contract larg outsid organ servic line
employ model
evalu whether make sens contract employ
model continu evolv
fy run hsd margin level
time get reason mid-teen rang
mostli outpati impact
littl effect inpatientrel nomin impact
creat nurs school educ program scale across
final stage plan expand nurs school
nurs continu nurs educ
invest would modest thisitd
oper select strong leadership
thing physician continu educ
consist past year
what go market
kept consist wage level consist guidanc
impact revenu earn significantli
polici support relat support patient
support commerci price side
complic patient discern
administr difficult complic
mani system struggl
doesnt anticip creat contract disrupt
posit well contract price standpoint
sierra la vega
make signific invest
larg part medic staff particip sierra contract
repatri exist facil
continu work earli part
modest impact flu
em volum ground ambul
trauma program
comprehens stroke capabl also yield traffic
oper process improv throughout year
time discharg drop
yield capac patient satisfact
go see larg impact
lower trend due medic admiss
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin januari
analyst suzi yoon amato michael newshel primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
